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Abstract
Relapsed pediatric acute lymphoblastic leukemia (ALL) has high rates of treatment failure.
Epigenetic regulators have been proposed as modulators of chemoresistance, here we sequence
genes encoding epigenetic regulators in matched diagnosis-remission-relapse ALL samples. We
find significant enrichment of mutations in epigenetic regulators at relapse with recurrent somatic
mutations in SETD2, CREBBP, MSH6, KDM6A and MLL2, mutations in signaling factors are not
enriched. Somatic alterations in SETD2, including frameshift and nonsense mutations, are present
at 12% in a large de novo ALL patient cohort. We conclude that the enrichment of mutations in
epigenetic regulators at relapse is consistent with a role in mediating therapy resistance.
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tIntroduction
Relapse occurs in 15 to 20% of pediatric acute lymphoblastic leukemia (ALL) and 50% of
adult ALL patients. Compared to de novo leukemia, relapsed leukemia is chemoresistant and
long term survival is poor, however the genetic basis for this is not well understood. Studies
of matched diagnosis and relapse ALL samples by SNP arrays demonstrated that 92% of
relapsed ALL had DNA copy number variant (CNV) changes from diagnosis. Surprisingly,
over half of relapses are missing CNVs present in the predominant clone at diagnosis and
appear to have derived from a minor subclone in many cases1. Targeting alterations that are
frequently gained at relapse is therefore a rational therapeutic strategy, as these lesions are
likely associated with chemotherapy resistance and clonal survival. Unfortunately, most
CNV alterations gained at ALL relapse are difficult to target, such as CDKN2A or ETV6
deletion.
Alterations in epigenetic regulators have recently been identified in genome and exome
sequencing studies of chemotherapy resistant, very high risk subsets of de novo ALL. For
example, 48% of early T-cell precursor (ETP) ALL2 and 60% of hypodiploid ALL3 have
somatic mutations in genes encoding epigenetic regulators. In addition, loss of function
mutations in the histone acetyltransferase CREBBP have also been described in diagnostic
samples from ALL patients who relapse and in samples from relapsed patients4. As the
enzymatic activities of CREBBP are directly opposed by histone deacetylases, this provided
one possible rationale for why histone deacetylase inhibitors have activity in ALL. These
studies suggest a broader paradigm in that mutations in epigenetic regulators may be
associated with therapy resistance and can be targeted indirectly through inhibition of the
enzymatic activity of opposing regulators. However, thus far, no published study has
addressed the mutational frequency of epigenetic regulators at ALL relapse, and whether
they are frequently enriched at relapse compared to at diagnosis.
Here we sequence matched sets of diagnosis-remission-relapse samples from pediatric ALL
patients, and find a significant enrichment of mutations in epigenetic regulators at relapse,
including the H3K36 trimethyltransferase SETD2. We conclude that these mutations are
likely involved in chemotherapy resistance and deserve further study to define their role in
the prognosis and treatment of ALL.
Results
Somatic mutations in epigenetic regulators in de novo ALL
In order to study this, we performed custom exon hybrid capture and Illumina sequencing of
472 known and putative epigenetic regulators and frequently mutated genes in leukemia
(Supplementary Table 1) on matched diagnostic-remission samples from 60 pediatric B-
ALL patients, and matched relapse samples from 30 of those patients that relapsed. Patients
in this cohort were those with pediatric ALL (primarily B-cell), with a range of cytogenetics
and risk groups (Supplementary Table 2). In this cohort, relapsed patients had the bone
marrow as a site of relapse, with over 60% marrow involvement. 70% of patients had an
identified somatic mutation at diagnosis and/or relapse (Fig 1).
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tConsidering only samples from the time of diagnosis, somatic variants in epigenetic
regulators were found in 25% of 60 B-ALL samples (Fig 2), which was similar to de novo
T-ALL patients5. In contrast, 50% of B-ALL samples harbored a mutation in a signaling
factor at diagnosis with recurrent mutations in the Ras pathway, including activating point
mutations in KRAS and NRAS, which were often subclonal (Supplementary Fig. 1A). At
diagnosis, recurrent mutations in epigenetic regulator genes were identified in CREBBP
(10%) and SETD2 (5%).
SETD2 mutations in de novo ALL
To more accurately determine the frequency of SETD2 mutations, which have not been
previously described in B-ALL, the coding regions of SETD2 were PCR amplified and
Illumina sequenced in a more representative independent validation cohort of 125 de novo
pediatric ALL patients. SETD2 mutations were found in 12% of the cohort and these
leukemias also frequently harbored mutations in the Ras pathway (Fig 3A). Four patients
harbored multiple SETD2 mutations. In total, we identified 24 SETD2 mutations in 19 out of
185 ALL patients, including seven loss of function frameshift or nonsense mutations, with
no obvious hotspot mutations (Fig 3B). Altogether, SETD2 mutations were most prevalent
in the MLL rearranged (22%) and ETV6-RUNX1 rearranged (13%) subtypes of ALL
(Supplementary table 3). Of note, these two subtypes were underrepresented in the initial
cohort, explaining the lower prevalence of SETD2 mutations in that cohort.
Enrichment of mutations in epigenetic regulators at relapse
Sequencing of the 30 matched relapsed samples showed a striking gain of mutations in
epigenetic regulators, with 17 (57%) harboring a mutation. Of the 11 patients that gained a
mutation in an epigenetic regulator at the time of relapse, only three were detectable in a rare
subclone at diagnosis. (Fig 4A). As noted above, this frequency is comparable to other poor
prognosis de novo ALL subgroups such as hypodiploid and ETP ALL. In addition to the 11
gains, five patients retained the same mutations from diagnosis, and one patient had their
clonal mutation reduced to a subclonal allele frequency at relapse (Supplementary Fig. 1B).
Details of each identified somatic mutation in each patient and a summary of mutations by
molecular subtype are available in the supplemental materials (Supplementary Tables 3 and
4).
By McNemar test, there was a statistically significant enrichment of the entire epigenetic
group (p=0.0039) (Fig 4B) and SETD2 and CREBBP together (p=0.045). In contrast, there
was not a significant enrichment of somatic mutations in signaling factors such as NRAS,
KRAS, FLT3 and JAK2, as individual genes, or as a group. This was because there were as
many patients gaining signaling mutations or mutational allele frequency as those losing
them (six, McNemar test p=1.00) (Fig 4B). The selective enrichment of epigenetic
regulators is consistent with the hypothesis that mutations in genes encoding epigenetic
regulators mediate chemotherapy resistance. Conversely, oncogenic mutations in signaling
factors showed no enrichment, with frequent losses and gains, implying no direct role in
modulating drug resistance and non-dependence on any particular mutation. Thus, solely
targeting signaling factors by specific inhibition may not circumvent the development of
chemoresistance. In total, recurrently mutated epigenetic regulators included MLL2, KDM6A
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tand MSH6, as well as additional mutations in SETD2 and CREBBP. KDM6A encodes for a
H3K27 demethylase. We recently reported somatic KDM6A mutations in 4% of pediatric
ALL at diagnosis, with mutations clustered in the catalytic jmjC domain6. SETD2 is the sole
mammalian H3K36 trimethyltransferase and mutations in it have been described in ETP T-
ALL2 and clear cell renal cell carcinoma7, but SETD2 has not been found to be recurrently
mutated in large cohorts of non-ETP T-ALL2,5,8 and AML9 patients.
MSH6 is a vital component of the DNA mismatch repair (MMR) machinery that localizes to
chromatin by binding to the H3K36 trimethyl mark that SETD2 makes. SETD2 knockdown
has been shown to cause mis-localization of MSH6 and microsatellite instability and a
mutator phenotype in several cell types10.
Discussion
Here, we report that somatic mutations in epigenetic regulators are enriched at relapse in
pediatric B-ALL with CREBBP, KDM6A, MLL2, SETD2 and MSH6 as recurrently mutated
genes. This finding suggests that therapy may be applying pressure to acquire or select for
rare subclones which possess these mutations. As noted above, SETD2 and MSH6 have
been linked together in DNA mismatch repair via the H3K36 trimethyl mark. We speculate
that the loss-of-function mutations identified in SETD2 and MSH6 may lead to clonal
survival by at least two possible mechanisms. One, a mutator phenotype induced by SETD2
inactivation could increase the mutational diversity and thus adaptability of the leukemia,
leading to clonal survival. Two, since intact MMR is important for triggering apoptosis
and/or cell cycle arrest in response to many DNA damaging chemotherapies, SETD2 loss
may lead to chemotherapy tolerance. For example, leukemia cells lines with defective MMR
show chemoresistance to the thiopurines 6-MP and 6-TG11, which are commonly used in
ALL therapy. These mechanisms are potentially reversible by inhibiting the epigenetic
regulators that oppose SETD2 activity such as the H3K36 demethylases.
Interestingly, alterations in other factors which modify H3K36 methylation, such as NSD1,
WHSC1/NSD2, NSD3, and KDM4A have been associated with ALL, AML, multiple
myeloma, breast cancer and myelodysplastic syndrome12. Several recent reports have
identified recurrent activating WHSC1/NSD2 E1099K mutations in many ALL cell lines and
20% of ETV6-RUNX1 translocated ALL patients13,14
The genetic basis for chemoresistance and poor outcomes in relapsed ALL is beginning to
be defined. This study identifies mutations in genes encoding epigenetic regulators as
frequently gained at the time of relapse. Although this study was not powered to determine a
prognostic effect of these mutations in this modest cohort of patients, the enrichment of
mutations in epigenetic regulators in relapsed B-ALL and other chemoresistant, high risk
subtypes of de novo leukemia is quite suggestive of a role in clonal survival. Epigenetic
regulators deserve particular attention because they are amenable to pharmacological
modulation. Histone deacetylase inhibitors are currently in clinical use15, and histone
methyltransferase inhibitors, such as DOT1L inhibitors16, are in clinical development.
Although these epigenetic therapies are first being evaluated in the relapsed setting, our
work also suggests that incorporating epigenetic therapies in upfront therapy, particularly in
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tpatients with identified mutations, could be a strategy to prevent the development of
chemoresistance and relapse.
Further studies are warranted to define the prognostic value of mutations in epigenetic
regulators in ALL, their effects on chemotherapy resistance and whether therapeutic
modulation of H3K36 methylation levels is a viable therapeutic strategy to prevent and treat
relapse in patients with leukemia.
Methods
Patient materials
Subjects were pediatric acute lymphoblastic patients enrolled and banked on upfront therapy
protocols DFCI 00-001, DFCI 05-001, AIEOP-2000, AIEOP-2006 or Interfant-99 and their
families each gave informed consent for future biological research on their banked samples
under protocols approved by the Institutional Review Board at each participating institution
and Dana Farber Cancer Institute. Bone marrow specimens were primarily used, but
peripheral blood was used for remission samples, if no bone marrow sample was available.
Diagnostic and relapse marrow samples had at least 60% blasts by morphology.
Mononuclear cells from each sample were isolated with Ficoll density gradient
centrifugation, and genomic DNA was extracted.
Exon capture
For exon capture, 1–2ug of genomic DNA was sheared with a Covaris E100 to an average
size of 200bp. Sheared DNA was end repaired, a-tailed, and ligated to barcoded adapters as
per the Illumina Truseq Library Preparation protocol. Libraries were amplified with the
Kapa Realtime Library Amplification kit into order to minimize the number of PCR cycles
used (range 4–12). Library was then quantified by Kapa Realtime Quantification Kit and
pooled up to 6 samples per lane in equimolar amounts totaling 500ng of DNA. Each pool
was then hybridized to a custom SureSelect In Solution Hybrid Capture RNA baitset,
consisting of 19,952 baits, spanning 2.35 Mb and 472 genes (Supplementary Table 1). Each
capture was washed and amplified with the Kapa Realtime Library Amplification Kit and
submitted for sequencing on an Illumina HiSeq 2000 100bp single end run.
Amplicon sequencing
192 primer pairs spanning the coding regions of SETD2, NRAS, KRAS, FLT3, JAK2,
PTPN11, TP53 and CDKN2A were designed and pooled into 48 primer pools and used for
amplification in the Fluidigm All Access Array (Supplementary Table 5). 50ng of genomic
DNA samples from 128 patients, 48 samples at a time with 48 primers pools, were amplified
by the Fluidigm All Access microfluidics system and each tagged with a unique barcode. All
samples were then pooled into one Illumina Hiseq 2000 100bp single end run.
Variant Calling
Fastq files were aligned to hg19 version of the human genome with BWA. SNP, indel and
copy number variant calling was performed with samtools mpileup and Varscan 2.2.3
somatic option. Annovar was used to annotate variants. Relapsed and diagnostic variants
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twere linked and variants were filtered for >=15% allele frequency and 20x coverage in
either tumor sample, <5% and 10x coverage in the remission sample, bidirectional variant
reads, minimal strand bias, and minimal local noise. Variants were visualized in the
Integrated Genome Viewer to eliminate variants with clustered read position and variants
caused by indel artifacts. Sanger sequencing was used to validate a sample of somatic
variants found by next generation sequencing to validate filtering criteria. Every filtered
somatic variant position was then forced called on every sample to examine the baseline
noisiness of each position. Those with mean baselines >1% allele frequency in remission
samples were excluded. Variants were also filtered to only those positions within 50 base
pairs of those included in the custom capture baitset. Variants were considered somatic if
they were present in less than 5% allele frequency in the paired remission sample (to
account for high minimal residual disease).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Targeted hybrid capture sequencing identified somatic mutations in 70% of BALL
patients
Matched tumor-remission samples from 60 pediatric B-ALL were sequenced with targeted
hybrid capture and somatic mutations in any tumor sample were identified. Genes on the left
are organized by mutational frequency. The type of alteration is identified for each mutation
as frameshift/stop, missense or splice site mutation. MLL: MLL rearranged, HYPO:
Hypodiploidy, iAMP21: intrachromosomal amplification of chromosome 21, HYPER:
Hyperdiploidy.
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tFigure 2. Mutations in epigenetic regulators occur in 25% of B-ALL patients at diagnosis,
including SETD2
Matched diagnosis and remission sample pairs from 60 pediatric B-ALL patients were
baited with target hybrid capture, Illumina sequenced and somatic mutations were identified.
Patients are organized by those that eventually relapsed (on the left), and those that did not
(on the right). Final risk category and molecular subtypes listed below. MLL: MLL
rearranged, HYPO: Hypodiploidy, iAMP21: intrachromosomal amplification of
chromosome 21, HYPER: Hyperdiploidy.
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tFigure 3. SETD2 Mutations in de novo ALL
A) Amplification and Illumina sequencing of coding exons of SETD2 and other frequently
mutated genes in an validation cohort of 125 de novo ALL patients identified 20 additional
SETD2 mutations in 15 patients (12%). Relapse status is noted above. Final risk category
and molecular subtypes listed below. MLL: MLL rearranged, HYPO: Hypodiploidy,
iAMP21: intrachromosomal amplification of chromosome 21, HYPER: Hyperdiploidy. B)
Schematic of somatic SETD2 mutations found in ALL patients.
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tFigure 4. Relapsed B-ALL is enriched for mutations in epigenetic regulators
A) Gain or loss of somatic mutations in matched diagnosis-relapse samples from 30
pediatric B-ALL patients. Clonal mutations at relapse which were detected in a minor
subclone at diagnosis and clonal mutations at diagnosis which became subclonal at relapse
are shaded. MLL: MLL rearranged, HYPO: Hypodiploidy, iAMP21: intrachromosomal
amplification of chromosome 21, HYPER: Hyperdiploidy. B) Comparison of the number of
patients which gain, lose, or have the same number of mutations in epigenetic regulators and
signaling factors at relapse. The McNemar test was used to calculate the P-values.
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